Julián NMA, Miranda NMG, Flores REM, Guerra GI, Solórzano SF, Vázquez RJG

Language: Spanish
References: 26
Page: 355-366
PDF size: 256.35 Kb.

ABSTRACT

Background. In regard to transplant-associated complications, infections represent one of the principal causes of death and graft loss. Of these, viral infections are the principal cause. The aim of this study was to determine the frequency of infection and/or disease due to cytomegalovirus (CMV) and clinical presentation in a cohort of pediatric kidney transplant patients as well as to present the risk factors associated with its development.
Methods. We carried out a retrospective cohort study. Clinical files of patients who underwent kidney transplantation between 2004 and 2006 and with a minimum of 6 months of follow-up were reviewed. Active infection was considered if a positive IgM to CMV after transplant was detected or seroconversion or positive pp65 antigenemia or CMV-DNA positive PCR test. Cases represented patients with active infection or disease and controls were patients without infection and/or disease. Risk factors investigated were age, serological status previous to transplant, donor, drug prophylaxis, year of transplant and blood transfusions.
Results. Of 120 transplant patients, 81 fulfilled the inclusion criteria; 53% were male and 47% female with a median age of 12 years. During follow-up, four patients presented a probable infection (4.9%), ten patients had active infection (12.3%), two patients had CMV disease (2.5%), and one patient experienced rejection plus infection (1.2%). Fifteen patients presented rejection due to different causes (18%) and 49 patients (60.5%) did not develop complications. The only significant risk factor for development of infection or disease was a previous negative serological status for CMV (OR 3.58 95% CI 0.94-14.74, p = 0.035). Frequency of infection was higher in the year 2004 (12/17 patients). Prophylaxis was administered correctly in only 28.9% of the patients.
Conclusions. Frequency of CMV infection in pediatric kidney transplant patients was 20%. Among high-risk groups, frequency was 34% and decreased to 9% among low-risk groups. Most infected patients were asymptomatic, 30% presented general symptoms and 10% presented specific signs of CMV disease. Serological diagnosis was performed for most of the cases (IgM to CMV). The only significant risk factor for development of CMV infection was negative serological status for CMV previous to transplant.

REFERENCES

1. Tejani A, Harmor WE. Pediatric renal transplantation. En: Owen W, Pereira B, Sayegh M, eds. Dyalisis and Transplantation. Philadelphia: W.B. Saunders; 2000. pp. 629-652.

2. Tolkoff-Rubin N, Rubin R. Infection in the renal transplant recipient. En: Owen W, Pereira B, Sayegh M, eds. Dyalisis and Transplantation. Philadelphia: W.B. Saunders; 2000. pp. 584-594.

3. Snydmann DR. Epidemiology of infections after solid-organ transplantation. Clin Infect Dis 2001;33(suppl 1):S5-S8.

4. Crumpacker CD. Cytomegaloviurs. En: Mandell GL, Bennet JE, Dolir R, eds. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone; 2001. pp. 1586-1598.

5. Limaye AP, Bakthavatsalam R, Kim HW, Randolph S, Halldorson J, Healey P, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Trasplantation 2006;81:1645-1652.

6. Rowshani AT, Bemelnan FJ, Van Leeuwen EM, van Lier RA, Berge IJ. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2005;79:381-386.

7. Ljungmann P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-1097.

8. Green M, Michaels M. Preemptive therapy of cytomegalovirus disease in pediatric transplant recipients. Pediatr Infect Dis J 2000;19:875-877.

9. Gandhi M, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004;4:725-738.

10. Schaade L, Kockelkorn P, Ritter K, Kleines M. Detection of cytomegalovirus DNA in human specimens by light-cycler PCR. J Clin Microbiol 2000;38:4006-4009.

11. Hernando S, Folgueira L, Lumbreras C, San Juan R, Maldonado S, Prieto C, et al. Comparison of cytomegalovirus viral load measure by real-time PCR with pp65 antigenemia for the diagnosis of cytomegalovirus disease in solid organ transplant patients. Transplant Proc 2005;37:4094-4096.

12. Kalil AC, Levitsky JL, Lyden E, Stoner J, Freifeld AG. Metaanalysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870-880.

13. Strippoli GF, Hodson E, Jones C, Craig JC. Pre-emptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006;81:139-145.

14. Snydman D. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis. Clin Infect Dis 2005;40:709-712.

15. Couchoud–Heyer C. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation. Cochrane Renal Group. Cochrane Database Syst Rev 2000;2:CD001320.

16. Humar A, Siegal D, Moussa G, Kumar D. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 2005;192:1154-1157.

17. Díaz-Pedroche C, Lumbreras C, Del Valle P, San Juan R, Hernando S, Folgueira D, et al. Efficacy and safety of valganciclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients. Trasplant Proc 2005;37:3766-3767.

18. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener M, Cacciarelli T. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact of viral load and late-onset cytomegalovirus disease. Trasplantation 2005;79:85-90.

19. Echániz-Aviles G, Tamayo-Legorreta E, Cruz-Valdéz A, Rangel- Flores H, Hernández-Nevárez P, Gatica-Marquina R, et al. Prevalencia de anticuerpos contra citomegalovirus en mujeres en edad reproductiva. Salud Publica Mex 1993;35:20-26.

20. Polanco-Marín G, Puerto-Manzano FI, Puerto-Solís M, González-Losa M, Albertos-Alpuche NE, Baeza-Becab MA. Prevalencia e incidencia de infección por citomegalovirus en mujeres embarazadas del estado de Yucatán, México. Rev Biomed 1996;7:127-131.

21. Bernard M. Complicaciones infecciosas del transplante renal y su tratamiento. En: Danovitch GM, ed. Transplante Renal. Los Angeles: Marban; 2002. pp. 221-262.

22. Khoury JA, Brennan DC. Infectious complications in kidney transplant recipients: review of the literature. Saudi J Kidney Dis Transpl 2005;16:453-497.

23. Martín-Dávila P, Abete-Fortún J. Cytomegalovirus infection in kidney transplant patients: what is the best way to prevent it? Nefrologia 2008;28:253-256.

24. Kanter J, Pallardo L, Gavela E, Escudero V, Beltrán S, Morales A, et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome. Trasplant Proc 2009;41:2156-2158.

25. Smith SR, Butterly DW, Alexander BD, Greenberg A. Viral infections after renal transplantation. Am J Kidney Dis 2001;37:659-676.

26. Bedel AN, Hemmelgarn TS, Kohli R. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir. Liver Transpl 2012;18:347-354.